Non Hodgkin's Lymphoma News and Research

RSS

The Non-Hodgkin lymphomas (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma.

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

High BMI in late teens linked to higher risk of 17 different cancers later in life

Men who are overweight or obese at age 18 have a higher risk of 17 different cancers later in life. This has been shown in a study at the University of Gothenburg.

6 Nov 2023

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Researchers examined the association between moderate alcohol intake and specific cancer risks.

21 Aug 2023

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

13 Jun 2023

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

The Pediatric Cancer Research Foundation, a nonproﬁt focused on transforming pediatric cancer care by accelerating research breakthroughs, today announced the 19 recipients of its 2023 research grants.

26 May 2023

Formerly incarcerated persons have higher health risks than the general population

In 2012, Michael Cruz exercised a lot. Four years into a 15-year prison sentence, this was one of the only things he had, he says, until he noticed a numb, tingling sensation in one of his toes while working out.

3 Apr 2023

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body.

27 Jan 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

International collaboration secures €1M grant to investigate new treatment target for lymphoma

An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

25 Nov 2021

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

A research group from the US (led by experts from Yale University School of Medicine) recently presented a case of an immunocompromised female patient with acquired deficiency of B lymphocytes who subsequently developed a protracted course of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

A new class of drugs that inhibits a "master switch" involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai.

22 Jun 2021

MDC researchers develop a potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

11 Jan 2021

Regulating fas protein may be a route to prevent cancer relapse after immunotherapy

Mount Sinai researchers have solved one of the enduring mysteries of cancer immunotherapy: Why does it completely eliminate tumors in many patients, even when not all the cells in those tumors have the molecular target that the therapy is aimed at?

17 Dec 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process.

1 Oct 2020

FDA provides update on adverse events associated with breast implants

Today, the U.S. Food and Drug Administration is providing an update on adverse events reported to the Agency related to breast implants, including breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and systemic signs and symptoms referred to by patients as breast implant illness (BII), which some patients report after receiving breast implants.

20 Aug 2020

New cancer vaccine shows promising signs in preclinical studies

Scientists are ready to trial a new cancer vaccine in humans following the successful outcome of their preclinical studies.

9 Jul 2020

People with a cancer history have increased risk of developing atrial fibrillation

People with a history of cancer have an over two-fold risk of developing atrial fibrillation (AFib), the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

18 Mar 2020